Integer Holdings Corporation Faces Class Action Lawsuit with Deadline for Claims by February 9, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Lawsuit Background: Levi & Korsinsky LLP has initiated a class action lawsuit against Integer Holdings Corporation, alleging securities fraud from July 25, 2024, to October 22, 2025, which has adversely affected investor confidence and led to a decline in stock price.
- False Statements: The complaint alleges that Integer overstated its competitive position in the electrophysiology manufacturing market and concealed deteriorating sales of its electrophysiology devices, misleading investors about the company's growth prospects.
- Claim Information: Affected investors must apply by February 9, 2026, to be appointed as lead plaintiffs to participate in potential compensation, with no out-of-pocket costs or fees required to join the lawsuit.
- Legal Team Strength: Levi & Korsinsky has over 20 years of experience in securities litigation, securing hundreds of millions for aggrieved shareholders, and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years, demonstrating its expertise in complex cases.
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 91.75 USD with a low forecast of 69.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 84.700
Low
69.00
Averages
91.75
High
140.00
Current: 84.700
Low
69.00
Averages
91.75
High
140.00
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
